Related Experiment Videos
Controlled trial of acebutolol in hypertension
Insights
Acebutolol effectively lowers blood pressure and heart rate in patients with essential hypertension. This cardioselective beta-blocker offers a significant therapeutic option for managing high blood pressure.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Hypertension is a prevalent cardiovascular condition requiring effective management.
- Cardioselective beta-adrenoceptor blocking agents represent a key therapeutic class for hypertension.
Purpose of the Study:
- To evaluate the efficacy of acebutolol in treating essential hypertension.
- To assess the dose-dependent effects of acebutolol on blood pressure and heart rate.
Main Methods:
- A double-bind, placebo-controlled study was conducted.
- Thirty-eight male patients with essential hypertension were randomized to receive placebo or acebutolol (400, 600, 1200 mg/day) for 12 weeks.
- Blood pressure and heart rate were monitored at 4-week intervals.
Main Results:
- Acebutolol treatment resulted in statistically significant reductions in both systolic and diastolic blood pressure compared to placebo.
- Heart rate was also significantly decreased in patients treated with acebutolol.
- The reductions in blood pressure and heart rate were observed across the tested dosage range of acebutolol.
Conclusions:
- Acebutolol is an effective agent for the treatment of essential hypertension.
- The study demonstrates the antihypertensive and heart rate-lowering properties of acebutolol.
- Acebutolol represents a valuable therapeutic option for managing hypertension.
Abstract:
Acebutolol, a new cardioselective beta-adrenoceptor blocking agent, has been evaluated for the treatment of hypertension. Thirty eight previously untreated male patients with essential hypertension received placebo treatment during a 4-week run-in period, and then they were randomly (double-bind) allocated either to continued placebo treatment for three 4-week periods or to treatment with acebutolol 400, 600, and 1200 mg daily, respectively, for three 4-week periods. Blood pressure and heart rate were recorded at the end of each 4-week period. Treatment with acebutolol produced statistically significant reductions in blood pressure and heart rate as compared to the placebo regimen.